Curis Inc
NASDAQ:CRIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Carlit Holdings Co Ltd
TSE:4275
|
JP |
|
Kirloskar Oil Engines Ltd
NSE:KIRLOSENG
|
IN |
|
R
|
Rimoni Industries Ltd
TASE:RIMO
|
IL |
|
Sterling and Wilson Renewable Energy Ltd
NSE:SWSOLAR
|
IN |
|
Cloud Factory Technology Holdings Ltd
HKEX:2512
|
CN |
|
T
|
Tt Vision Holdings Bhd
KLSE:TTVHB
|
MY |
|
C
|
Chengdu Bright Eye Hospital Co Ltd
SZSE:301239
|
CN |
|
Launch Tech Co Ltd
HKEX:2488
|
CN |
|
Lucky Harvest Co Ltd
SZSE:002965
|
CN |
|
Guosheng Financial Holding Inc
SZSE:002670
|
CN |
Curis Inc
Depreciation & Amortization
Curis Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Curis Inc
NASDAQ:CRIS
|
Depreciation & Amortization
$169k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Curis Inc
Glance View
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
See Also
What is Curis Inc's Depreciation & Amortization?
Depreciation & Amortization
169k
USD
Based on the financial report for Dec 31, 2025, Curis Inc's Depreciation & Amortization amounts to 169k USD.
What is Curis Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
1%
Over the last year, the Depreciation & Amortization growth was -17%. The average annual Depreciation & Amortization growth rates for Curis Inc have been -10% over the past three years , 4% over the past five years , and 1% over the past ten years .
